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What Are Birth Defects? 
 An abnormality affecting body structure or function  
that is present at birth 
 May be obvious at birth  
 May not be obvious at birth and diagnosed later in life 
 Functional defects include developmental disabilities  
(e.g., cerebral palsy or deafness) 
 Structural defects include two types 
 Major malformation    
 Surgical, medical or cosmetic importance 
 Minor malformation 




Single palmar crease 
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Major Birth Defects Are Common 
 1 in 33 or 3% of   
children born are 
identified at birth 
 120,000 babies each 
year in the US 
 Prevalence increases 
to 1 in 20 or 5% by 5 
years of age   
 





2% Neural tube defects 





Type of Birth Defect 
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Heart Defects  
Hypoplastic Left 
Heart Syndrome 




These types of defects will require surgical repair 
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Neural Tube Defects 
Spina bifida Anencephaly 
8 
Abdominal Wall Defects 
Gastroschisis Omphalocele 
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Birth Defects Are Costly 
 CDC. MMWR Morb Mortal Wkly Rep. Jan 19, 2007 
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Average daily hospital charges per newborn 
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Birth Defects Are Costly 
 In 2004, hospitalizations 
and medical charges 
cost $2.6 billion per year 
for all ages 
Medical care and 
advances in technology 
have improved long-term 
survival among children 
with birth defects 
 
 
Russo CA, Elixhauser A. HCUP Statistical Briefs : Agency for Health Care Policy and Research (US); 2006-.2007 Jan.  
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Birth Defects Are Critical   
 
 Infant mortality 
 6.7 deaths per  
1,000 infants 
 21% of deaths in the  
first year of life are due 
to  birth defects 
 Congenital heart defects 
represent largest group 
 
Leading Causes of  
Infant Mortality, 2011 
LBW: Low  birth weight 















Most Major Birth Defects Occur Early in Pregnancy 
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Pregnancy Planning is  
Primary Prevention of Birth Defects  
 
 The critical time period for all women to reduce their 
risk is before they become pregnant 
 To reduce the risk of a neural tube defect, a woman 
must consume folic acid before conception  
 Folic acid fortification of cereals and grains has been 
very effective because it increases folate levels 
among women in the US, whether planning a 
pregnancy or not 
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Increasing Prevalence of Gastroschisis 
Suggests Environmental Influence 































Year of Birth 
Trends in Gastroschisis Prevalence by Maternal 
Age Group, 1995-2005 
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 The Majority of Birth Defects  
Do Not Have an Identifiable Cause  
 
Utah Birth Defect Network, Utah Department of Health 
 
Teratogen:  




in an embryo 
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Working to Identify the Unknown Causes 
Major birth defects should be systematically 
monitored in the population 
 Environmental factors that women are exposed to 
should be investigated  
Major birth defects are common, costly and critical 
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Advancing Understanding of the  
Causes of Birth Defects 
 
Jennita Reefhuis, PhD 
Epidemiology Team Lead 
Birth Defects Branch 
Division of Birth Defects and Developmental Disabilities 
National Center on Birth Defects and Developmental Disabilities 
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How To Study Rare Outcomes  
Such as Specific Birth Defects 
 Cohort studies 
 Pro: Prospective exposure information 
 Con: Need a very large study to identify enough cases 
 Data-linkage studies 
 Pro: Cost-efficient 
 Con: Methods for mother-baby linkage challenging 
 Con: Limited diagnostic and exposure data 
 Pregnancy registries  
 Pro: Useful to identify major effects 
 Con: Not population based 
 
Tinker, S. C., Gilboa, S., Reefhuis, J., Jenkins, M. M., Schaeffer, M., & Moore, C. A. (2014). Current Epidemiology Reports, 1-8. 
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Studying Rare Birth Defects: The Best Option 
 Case-control studies 
 Pro: Efficient 
 Pro: High-quality diagnostic data 
 Pro: Ability to look at specific birth defects 
 Con: Needs to be multi-center or many years to have sufficient data 
 Con: Potential recall bias 
 
 Case-control studies are used to identify factors that may 
contribute to a medical condition by comparing subjects who 
have that condition (the "cases") with similar patients who do 
not have the condition (the "controls“) 
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National Birth Defects 
Prevention Study 
 Population-based case control study 
 Births October 1997-December 2011 
 Cases from state-based birth defects  
surveillance systems 
 Study cohort 
 ~ 6 million total live births 




NBDPS Data Collection Methods 
 Over 30 defects studied 
 Live-born control infants 
 Telephone interview with mothers of cases and controls 
 32,209 case mothers interviewed (67.4%) 
 11,805 control mothers interviewed (64.8%) 
 Buccal cell (cheek swab) requested from mother, 




NBDPS: National Birth Defects Prevention Study 
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Selected NBDPS Results 
 Over 200 peer-reviewed manuscripts 
 Diabetes diagnosed before pregnancy 
 Heart defects: odds ratio 4.6 (2.9 - 7.5) 
 Non-heart defects: odds ratio 2.3 (1.4 - 3.8) 
 Stress and neural tube defects 
 4 or more stressful life events in early pregnancy 
 Such as relative’s death, financial or legal problems, violence 
 Odds ratio 1.5 (1.1 - 2.0) 
 Perception of social support  
 Emotional, financial, daily tasks 
 Odds ratio 0.8 (0.5 - 1.1) 
Correa et al. AJOG 2008 
Carmichael et al. Paediatr Perinat Epidemiol 2014 
NBDPS: National Birth Defects Prevention Study 
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NBDPS Results: Exposure to Opioid Medications 
 Hypoplastic left heart syndrome 
 17 exposed cases 
 Odds ratio 2.4 (1.4 - 4.1) 
 Spina bifida 
 26 exposed cases 
 Odds ratio 2.0 (1.3 - 3.2) 
 Gastroschisis 
 26 exposed cases 
 Odds ratio 1.8 (1.1 - 2.9) 
 
 
Broussard et al. AJOG 2011 
NBDPS: National Birth Defects Prevention Study 
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Better Data to Help Inform Treatment Choices 
Maternal disease in pregnancy may need treatment 
 Disease can harm mother and baby (e.g., fever or diabetes) 
 Comparing risk-benefit of treatment compared with  
no treatment 
 Comparing birth defect risk of different treatments– 
some options may be safer  
 Choice of SSRIs for depression 
 Antibacterials in early pregnancy 
SSRIs: selective serotonin reuptake inhibitors 
www.cdc.gov/pregnancy/meds/treatingfortwo/ 
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Antibacterial Medication in Early Pregnancy 
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  Treating for Two Initiative 
 Expand research to fill knowledge gaps  
 Accelerate epidemiologic research into medication 
use and pregnancy outcomes 
 Evaluate evidence to develop  
reliable guidance 
 Establish ongoing systematic review of evidence and 
expert body to translate into summary guidance  
 Deliver information to support  
decision-making 
 Disseminate up-to-date, clinically relevant information 
to prescribers, pharmacists, patients, and consumers 
www.cdc.gov/pregnancy/meds/treatingfortwo/index.html 
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Exploring Modifiable Risk Factors –  
Medications with New and Expanded Uses 
 Pregnant women not included in clinical trials 
 Excluded because of safety concerns 
 Often use medications after licensure 
 New medications constantly introduced 
 Existing medications with new indications 
 Antiepileptic topiramate used as weight-loss product 
 Antiepileptics used to treat migraines 
 Want to include questions about why person              
is taking medicine, and at what dosage 
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Birth Defects Study To Evaluate 
Pregnancy Exposures 
 17 defects selected  
 Severity 
 Prevalence 
 Consistent ascertainment 
 7 centers 
 Arkansas, California, Georgia, Iowa,  
Massachusetts, New York, North Carolina 
 Births starting January 1, 2014 




Exploring Modifiable Risk Factors  
Maternal Disease and Treatment with Medications 
 Increased survival among women with 
 Cancer 
 Organ and tissue transplants 
 Increased prevalence 
 Asthma 
 Attention-deficit hyperactivity disorder 
 Assess diagnostic and treatment details 
 Diabetes 
 Mental health disorders 
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Going Beyond Case-Control Studies 
 To establish causation, confirmation of epidemiologic 
findings needed  
 Surgeon General’s 2014 report included a finding that smoking is 
causally related to orofacial clefts (such as cleft lip, cleft palate) 
 Isotretinoin and severe birth defects 
 Thalidomide and limb and other defects 
 Statistical modeling studies  
 Assess the prevention impact  
of substituting “safer” medications 
 
 
The health consequences of smoking: 50 years of progress.  A Report of the Surgeon General, 2014.  
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Birth Defects Work Must Continue 
 Important to remember that 1 in 33 pregnancies are 
affected by birth defects 
 Relatively common at the population level, but individual defects  
are rarer 
 CDC’s Birth Defects Branch and its collaborators 
continue to contribute to: 
 Identifying risk factors for birth defects among medicines, 
diseases, and environmental factors 
 Assessing risk-benefit of medications 
 Determining whether there are safer                                      safer 
treatment options for certain diseases 
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Birth Defects Research and Emergency  
Preparedness:  The Vaccines and Medications in 
Pregnancy Surveillance System 
 
 
Allen A. Mitchell, MD 
Director, Slone Epidemiology Center 
Professor of Epidemiology and Pediatrics, 
Boston University Schools of Public Health and Medicine 
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Trends in Medication Use During Pregnancy 
Pregnancy Health Interview Study (Birth Defects Study), Slone Epidemiology Center, Boston University 
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Specific Examples 
Medications whose exposure prevalence in 
pregnancy has increased in recent years include: 
 Selective serotonin reuptake inhibitors (SSRIs) 
 
 Attention deficit hyperactivity disorder medications, primarily 
amphetamine mixed salts  (e.g., Adderall®) 
 
Mitchell, et al. AJOG, 2015. 




What Are the Implications of Greater  
Medication Use During Pregnancy? 
 For the purposes of birth defects prevention, we 
need to focus on medications and vaccines for 
which: 




 Pregnancy exposure is common but data on pregnancy risk and 
safety are insufficient  
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Proportion of Women Receiving  


























Last Menstrual Period Year 
Exposed to any flu shot
 Unpublished data; Birth Defects Study, Slone Epidemiology Center, Boston University 
* Incomplete year 
* 
H1N1 influenza pandemic 
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Proportion of Women Receiving 






























Last Menstrual Period Year 
Exposed to Antiviral
* 
Unpublished data; Birth Defects Study, Slone Epidemiology Center, Boston University 
* Incomplete year 
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Proportion of Women Receiving  


























Last Menstrual Period Year 
Exposed to Tdap vaccine
* 
 Unpublished data; Birth Defects Study, Slone Epidemiology Center, Boston University 
 Tdap: Tetanus Toxoid, Diphtheria Toxoid, and Acellular Pertussis Vaccine 
* Incomplete year 
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How Do We Learn About  Risks and Relative Safety  
for “New” Exposures in Pregnancy? 
 Need to identify risks and 
relative safety of drugs, 
vaccines, and biologics 
(e.g., immune globulins) 
used by pregnant women  
 Particularly important to 
have a system that is agile 
in its ability to identify and 
study new products 
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 Specifically designed to assess the risks and safety 
of vaccines and medications used in pregnancy 
 Funding model is public-private partnership  
 Identifies wide range of relatively common adverse 
pregnancy outcomes, including birth defects overall  
 Has statistical power to evaluate specific birth 
defects and their possible causal relation to drugs  
or vaccines  
 
 Vaccines and Medications in 
 Pregnancy Surveillance System (VAMPSS) 
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Objectives of VAMPSS 
 Targets new (and old) drugs and vaccines recommended  
for use or have come into use during pregnancy  
 Current examples 
 Annual influenza, acellular pertussis vaccines 
 Future examples 
 Respiratory syncytial virus vaccines 
 Group B streptococcus vaccines  
 Emergent examples 
 Ebola vaccines, drugs, or biologics that might be licensed or approved  for 
emergency use                                                                                    
 Prospective cohort and case-control study arms can direct  




VAMPSS: Vaccines and Medications in Pregnancy Surveillance System 
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Structure of VAMPSS 
 
 
Organization of Teratology 
Information Specialists  
Research Center 
 at the University of  
California San Diego 
Tina Chambers, PhD, MPH 
Kenneth Lyons Jones, MD 
 
 
Slone Epidemiology Center  
at Boston University 
Allen A. Mitchell, MD 











Independent Advisory  
Committee 
American Academy of Allergy Asthma and Immunology 
Michael Schatz, MD, MS 
VAMPSS: Vaccines and Medications in Pregnancy Surveillance System                   ACOG: American Congress of Obstetricians and Gynecologists 
NICHD: National Institute of Child Health and Human Development                           AAP: American Academy of Pediatrics 
NIAID: National Institute of Allergy and Infectious Diseases 
Prospective Cohort   Case-Control Study  
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Prospective Cohort – Organization of 
Teratology Information Specialists 
 
 OTIS is a North American network of university or 
hospital-based services in existence since 1979 
 Specialists provide risk counseling to 80 - 100,000 
pregnant women and health care providers per year 
 Network can screen callers from a geographically 
diverse area to identify those who received a 
vaccine or medication of interest, along with an 
unexposed comparison group 
OTIS: Organization of Teratology Information Specialists 
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Participants of Prospective Cohort–OTIS 
 OTIS sites refer potential participants to 
coordinating center 
 An exposed cohort, a disease-matched cohort and a healthy 
unexposed cohort are concurrently recruited 
 Each cohort followed for birth defects overall, preterm birth, 
growth and spontaneous abortion 
 All groups receive  
 A series of structured telephone interviews at standard time 
points during and after pregnancy, and an outcome interview 




OTIS: Organization of Teratology Information Specialists 
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Data Collected from  
Prospective Cohort – OTIS 
 Maternal interviews and medical records review 
provide detailed information 
 Dose, timing, duration of medication and vaccine exposure 
 Maternal disease or indication for medication 
 Pregnancy history, health history, demographics 
 Wide range of potential confounders including  
 Other prescription or over-the counter medications  
 Body mass index  
 Tobacco, alcohol and vitamin and mineral use 
OTIS: Organization of Teratology Information Specialists 
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Case-Control–Birth Defects Study 
 BDS began in 1976 at Slone Epidemiology Center, 
Boston University 
 Objectives   
 Identify risks and safety of a wide range of medications and 
vaccines with respect to the wide range of specific birth defects 
 Establish ranges of risk for specific medications 
 Identify rates of exposure to specific agents 
 
 
BDS: Birth Defects Study 
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Case-Control Study Participants–BDS 
 Study participants 
 Infants with specific major congenital malformations (cases) 
 Infants without congenital malformations (controls) 
 Multi center design   
 Hospital and clinic surveillance  
 Greater metropolitan Boston, Philadelphia, San Diego, Nashville 
 Birth defects registries  
 Massachusetts, New York 
 
BDS: Birth Defects Study 
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Data Collected from  
Case-Control Study–BDS 
 Data obtained from mothers by computer-assisted 
telephone interview 
 Interviewed by study nurses within six months of delivery 
 Interview data include 
 Demographic and reproductive factors (e.g., age, education,  
number of previous pregnancies and births) 
 Medical history 
 Indications for use and use of prescription and OTC medications; 
including vaccines, vitamins and minerals, supplements  
 Wide range of potential confounders (e.g., smoking, alcohol, diet) 




VAMPSS and Pandemic H1N1 Influenza 
 Anticipating a pandemic caused by H1N1 influenza 
and the widespread use of the pH1N1 vaccine  
among pregnant women in 2009 - 2010 
 BARDA requested VAMPSS to monitor the risks and 
relative safety of the pandemic H1N1 vaccine and 
influenza antiviral drugs 
 
BARDA: Biomedical Advanced Research and Development Authority  
VAMPSS: Vaccines and medications in pregnancy surveillance system 
pH1N1: pandemic H1N1 influenza virus 
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Timeline for VAMPSS pH1N1 Studies 
 
VAMPSS: Vaccines and medications in pregnancy surveillance system   
pH1N1: pandemic H1N1 influenza virus 
CBER/FDA: Center for Biologics Evaluation and Research at the Food and Drug Administration        





















to           
ACIP 
 VAMPSS was able to quickly modify data collection 
to meet the objectives of safety monitoring for pH1N1 
vaccines and influenza antivirals in pregnant women 





Findings from VAMPSS pH1N1 Studies:  
No Increased Risk of Birth Defects 
Chambers CD, Johnson D, Xu R, Luo Y, Louik C, Mitchell AA et al. Vaccine. 2013 Oct 17;31(44):5026-32. 
Louik C, Ahrens K, Kerr S, Pyo J, Chambers C, Jones KL, et al. Vaccine. 2013 Oct 17;31(44):5033-40. 
VAMPSS: Vaccines and medications in pregnancy surveillance system  




Women exposed to a  
pH1N1 vaccine did NOT  
have an increased risk of   
having a baby born  
with a birth defect 
 
Relative risk = 0.79  
95% CI: 0.26 - 2.42  
 




For 41 specific defects,  
most adjusted odds ratios  
were close to 1.0,  
and most of those had  





Importance of VAMPSS for  
Public Health Emergency Response 
 Pregnant women may be at high risk for complications  
that endanger their pregnancies 
 Drugs, vaccines, or other medical products might be 
used in pregnant women with little or no study 
 VAMPSS is proven to work in monitoring safety of 
emergency countermeasures in pregnant women, on  
short notice 
 VAMPSS represents a key tool to maintain confidence 
among providers and the public that preventive 
measures are being actively monitored for safety 
 
VAMPSS: Vaccines and medications in pregnancy surveillance system  
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Identifying What Else We Can Do To 
Prevent Birth Defects 
 
Suzanne Gilboa, PhD, MHS 
Partnerships and Applied Epidemiology Team Lead 
Birth Defects Branch 
Division of Birth Defects and Developmental Disabilities 
National Center on Birth Defects and Developmental Disabilities 
 
54 
Folic Acid Fortification Prevents  
Neural Tube Defects 
 In 1992, the U.S. Public Health 
Service recommended all women of 
childbearing potential consume 
400μg folic acid daily 
 In 1998, enriched cereal grain 
products were required to be 
fortified at 140μg per 100g serving 
 Ready-to-eat cereals were allowed to 
be fortified up to 400μg per serving 
 
 










































NTD: Neural tube defects 
MMWR January 16, 2015 / 64(01);1-5 
 
 Prevented 15,000 cases of NTD 
since 1999 
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What Else Might Have An Impact  
on Birth Defects? 
 Use mathematical modeling of other risk factors to 
see how we might have a further impact 
 Obesity 
 Pregestational diabetes 
 Smoking 
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Basic Modeling Approach 
 Use data inputs from the published literature             
to estimate  
 Prevalence of the risk factor  
 Prevalence of the birth defect  
 Magnitude of association between risk factor and birth defects 
 If data not available from published literature, conduct a meta-
analysis to obtain a summary measure of association 
 Estimate the population attributable fraction for the  
risk factor 
 Estimate the number of preventable birth defects 
 Modeling incorporates uncertainty (e.g., Monte Carlo simulation) 
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Overall Obesity Trends in the United States 
CDC. U.S. Obesity Trends (www.cdc.gov/obesity/data/trends) 
By 2010, every state had 20% or greater prevalence of obesity 
1990 2010 
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Accounting for Uncertainty in the 
Prevalence of Prepregnancy Obesity 
 For pregnant women, prepregnancy prevalence-18.7%  
 PRAMS has self-reported height and weight data 
 For U.S. women 20 years or older, obesity prevalence-33% 
 NHANES has measured height and weight data 
 For U.S. women 20 years or older, obesity prevalence-20% 
 BRFSS has self-reported height and weight data 
Model used 18.7% estimate, plus bias factor based on 
NHANES measured data and BRFSS self-reported data 
 Bias factor accounts for differences in these estimates 
PRAMS: Pregnancy Risk Assessment Monitoring System 
NHANES: National Health and Nutrition Examination Survey  
BRFSS: Behavioral Risk Factor Surveillance System 
Chu et al. Matern Child Health J 2009 
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Input Data to Model the Impact of  




(Odds Ratio)  
Estimated 
Prevalence of 
Birth Defect  




with Birth Defect 
in US 
Congenital heart defects 1.30 81.4 33,960 
Spina bifida 2.24 3.5 1,460 
Cleft lip with or without 
cleft palate 
1.20 10.63 4,437 
* per 10,000 births 
Honein, et al. Obesity 2013. 
Stothard, et al. JAMA 2009. 
Reller, et al. J Pediatr 2008. 
Parker, et al. Birth Defects Res A Clin Molec Teratol 2010. 
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Estimates of the Impact of Reducing 
Prepregnancy Obesity on Birth Defects  
Annual Preventable Number  







If 100% Elimination  
of Prepregnancy 
Obesity 
If 10% Reduction  
in Prepregnancy 
Obesity 






















*  Population Attributable Fraction: The percent of cases estimated to be caused by prepregnancy obesity 
** Rounded to the nearest 5 
Honein, et al. Obesity 2013 
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Prevalence of Prepregnancy Diabetes 
 Among women of reproductive age, 
diabetes prevalence estimates vary 
between 1.9% and 4.0% 
 Additional 0.5% to 1% have 
undiagnosed diabetes 
Model used NHANES race-ethnicity 
specific prevalence estimates for 
women aged 20 - 44 
Simeone, et al. Am J Prev Med 2014. 
CDC. National Center for Health Statistics. Health Data Interactive. www.cdc.gov/nchs/hdi.htm. 
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Input Data to Model the Impact of  
Diabetes Control on Congenital Heart Defects 
Congenital Heart Defect 






in US*  
Estimated 
Annual Number 
of Children Born 
with Birth Defect 
All congenital heart 
defects 
3.8 81.4 32,182 
Coarctation of the aorta 3.7 4.5 1,767 
Hypoplastic left heart 
syndrome 
3.7 2.3 909 
Tetralogy of Fallot 6.5  4.0 1,570 
* per 10,000 live births 
Simeone, et al.  Am J Prev Med 2014. 
Reller, et al. J Ped 2008. 
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Estimates of the Impact of Diabetes Control on 
Congenital Heart Defects 
Annual Preventable Number  
(95% Uncertainty Interval)* 





























Hypoplastic left heart 
syndrome 
8.0%  





Tetralogy of Fallot 
14.8%  





* Rounded to the nearest 5 
Simeone, et al. Am J Prev Med 2014. 
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Potential Impact of Preconception Care on Costs 
Associated with Birth Defects 
Input Parameter Estimate 
Prevalence of pregestational diabetes 
Diagnosed:  2.9% (2.7%-3.2%) 
Undiagnosed: 0.5%  
Percent of births affected by birth 
defects among women with untreated 
pregestational diabetes 
7.3% 
Preconception care effectiveness, risk 
reduction 
0.25 (0.15 - 0.42) 
Lifetime costs of birth defects $411,723 
Peterson, et al. Am J Obstet Gynecol 2014.  
Hayes, et al. Prevent Chronic Dis 2011.  
Razzaghi, et al. Primary Care Diab 2013. 
Wahabi, et al. BMC Pregnancy Childbirth 2010. 
Waitzman, et al. Inquiry 1994. 
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Potential Impact of Preconception Care on Costs 
Associated with Birth Defects 
Outcome Estimate 
Birth defects averted 4,731  
(4,158–5,215) 
Total lifetime costs for birth 
defects averted 
$1.9 billion  
($1.7–$2.1 billion) 
Peterson, et al. Am J Obstet Gynecol 2014.  
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Smoking and Orofacial Clefts 
 50th Anniversary Surgeon General’s Report 
 Released in January 2014  
 Marked first confirmation of causal link between smoking in early 
pregnancy and orofacial clefts 
 Smoking is one of the few known                                 
risk factors for orofacial clefts                                        
with potential for prevention 
 Prevalence of smoking                                               
just before pregnancy: 23.2% 
PRAMS: Pregnancy Risk Assessment Monitoring System 
The health consequences of smoking: 50 years of progress.  A Report of the Surgeon General, 2014.  
Tong et al. MMWR Surveil Summ, 2013 
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Input Data to Model the Impact of  
Smoking Cessation on Orofacial Clefts 
* per 10,000 live births 
Honein, et al. Birth Defects Res Part A 2014.  
Hackshaw, et al. Human Reprod Update 2011.  
Birth Defect 










Born with Birth 
Defect 
Orofacial clefts 1.28 17.0 7088 
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Estimates of the Impact of Early Pregnancy  
Smoking Cessation on Orofacial Clefts 
* Rounded to the nearest 10 
Honein et al. Birth Defects Res Part A, 2014.  
Annual Preventable Number 




(95% Uncertainty Interval) 
If Elimination of Risk 








Advancing Prevention of Birth Defects 
 Birth defects are common, costly, 
and critical 
Majority of birth defects still do not have 
an identifiable cause 
 The causes are likely to be multi-factorial with an 
interaction between genetic factors and modifiable 
(environmental) risk factors 
 Based on the modifiable risk factors that 
have been recognized, we know that we 
can improve prevention 
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